Dr. Tomohiko Yamazaki is a principal researcher at the National Institute for Materials Science. He received his Ph.D. from the Tokyo University of Agriculture and Technology (TUAT) in 2000. During his Ph.D. studies, he joined Prof. Klaus Mosbach's group at Lund University, Sweden. He worked on the development of artificial enzymes using molecular imprinting techniques. After a 5-year postdoctoral career at TUAT (2000-2003) and the Tissue Engineering Research Center, National Institute of Advanced Industrial Science and Technology (2003-2005), he was an associate professor at the Graduate School of Technology Management at TUAT from 2005 to 2007. He moved to the NIMS in 2007. He is also a guest associate professor at the Graduate School of Life Science, Hokkaido University.
His current research interests include the development of novel bio-nanomolecules such as oligonucleotide-, peptide-, and protein-based materials, with knowledge gained from the life sciences. He seeks to utilize novel bio-nanomolecules in the diagnostics of and therapy for cancer, infection, and immunological disease.
Dr. Tomohiko Yamazaki is a principal researcher at the National Institute for Materials Science. He received his Ph.D. from the Tokyo University of Agriculture and Technology (TUAT) in 2000. During his Ph.D. studies, he joined Prof. Klaus Mosbach's group at Lund University, Sweden. He worked on the development of artificial enzymes using molecular imprinting techniques. After a 5-year postdoctoral career at TUAT (2000-2003) and the Tissue Engineering Research Center, National Institute of Advanced Industrial Science and Technology (2003-2005), he was an associate professor at the Graduate School of Technology Management at TUAT from 2005 to 2007. He moved to the NIMS in 2007. He is also a guest associate professor at the Graduate School of Life Science, Hokkaido University.
His current research interests include the development of novel bio-nanomolecules such as oligonucleotide-, peptide-, and protein-based materials, with knowledge gained from the life sciences. He seeks to utilize novel bio-nanomolecules in the diagnostics of and therapy for cancer, infection, and immunological disease.